Tuesday, 21 August 2012

Norvir Tablets





Dosage Form: tablet, oral solution
FULL PRESCRIBING INFORMATION
WARNING:

Co-administration of NORVIR with sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of certain drugs [see Contraindications (4) and Warnings and Precautions (5.1)].




Indications and Usage for Norvir Tablets


NORVIR is indicated in combination with other antiretroviral agents for the treatment of HIV-infection.



Norvir Tablets Dosage and Administration


NORVIR is administered orally. Norvir Tablets should be swallowed whole, and not chewed, broken or crushed. Take NORVIR with meals. Patients may improve the taste of NORVIR oral solution by mixing with chocolate milk, Ensure®, or Advera® within one hour of dosing.


General Dosing Guidelines


Patients who take the 600 mg twice daily soft gel capsule NORVIR dose may experience more gastrointestinal side effects such as nausea, vomiting, abdominal pain or diarrhea when switching from the soft gel capsule to the tablet formulation because of greater maximum plasma concentration (Cmax) achieved with the tablet formulation relative to the soft gel capsule [see Clinical Pharmacology (12.3)]. Patients should also be aware that these adverse events (gastrointestinal or paresthesias) may diminish as therapy is continued.


Dose Modification for NORVIR


Dose reduction of NORVIR is necessary when used with other protease inhibitors: amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir.


Prescribers should consult the full prescribing information and clinical study information of these protease inhibitors if they are co-administered with a reduced dose of ritonavir [see Warnings and Precautions (5) and Table 5, Established and Other Potentially Significant Drug Interactions].



Adult Patients


Recommended Dosage for Treatment of HIV-1.


The recommended dosage of ritonavir is 600 mg twice daily by mouth to be taken with meals. Use of a dose titration schedule may help to reduce treatment-emergent adverse events while maintaining appropriate ritonavir plasma levels. Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily. The maximum dose of 600 mg twice daily should not be exceeded upon completion of the titration.



Pediatric Patients


Ritonavir should be used in combination with other antiretroviral agents [see Dosage and Administration (2)]. The recommended dosage of ritonavir in children > 1 month is 350 to 400 mg/m2 twice daily by mouth to be taken with meals and should not exceed 600 mg twice daily. Ritonavir should be started at 250 mg/m2 and increased at 2 to 3 day intervals by 50 mg/m2 twice daily. If patients do not tolerate 400 mg/m2 twice daily due to adverse events, the highest tolerated dose may be used for maintenance therapy in combination with other antiretroviral agents, however, alternative therapy should be considered. When possible, dose should be administered using a calibrated dosing syringe.












































Table 1. Pediatric Dosage Guidelines
Body Surface Area (m2)Twice Daily Dose

250 mg/m2
Twice Daily Dose

300 mg/m2
Twice Daily Dose

350 mg/m2
Twice Daily Dose

400 mg/m2
0.200.6 mL (50 mg)0.75 mL (60 mg)0.9 mL (70 mg)1.0 mL (80 mg)
0.250.8 mL (62.5 mg)0.9 mL (75 mg)1.1 mL (87.5 mg)1.25 mL (100 mg)
0.501.6 mL (125 mg)1.9 mL (150 mg)2.2 mL (175 mg)2.5 mL (200 mg)
0.752.3 mL (187.5 mg)2.8 mL (225 mg)3.3 mL (262.5 mg)3.75 mL (300 mg)
1.003.1 mL (250 mg)3.75 mL (300 mg)4.4 mL (350 mg)5 mL (400 mg)
1.253.9 mL (312.5 mg)4.7 mL (375 mg)5.5 mL (437.5 mg)6.25 mL (500 mg)
1.504.7 mL (375 mg)5.6 mL (450 mg)6.6 mL (525 mg)7.5 mL (600 mg)

Body surface area (BSA) can be calculated as follows1:





Dosage Forms and Strengths


  • Norvir Tablets

White film-coated ovaloid tablets debossed with the corporate Abbott "A" logo and the Abbo-Code NK providing 100 mg ritonavir.


  • NORVIR Oral Solution

Orange-colored liquid containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg/mL).



Contraindications


  • When co-administering NORVIR with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information.

  • NORVIR is contraindicated in patients with known hypersensitivity (e.g. toxic epidermal necrolysis (TEN) or Stevens Johnson syndrome) to ritonavir or any of its ingredients.

  • Co-administration of NORVIR is contraindicated with the drugs listed in Table 2 because ritonavir mediated CYP3A inhibition can result in serious and/or life-threatening reactions. Voriconazole and St. John’s Wort are exceptions in that co-administration of NORVIR and voriconazole results in a significant decrease in plasma concentrations of voriconazole, and co-administration of NORVIR with St. John’s Wort may result in decreased ritonavir plasma concentrations.





































Table 2. Drugs that are Contraindicated with NORVIR
Drug ClassDrugs Within Class That Are Contraindicated With NORVIR**Clinical Comments:
Alpha1-adrenoreceptor antagonistAlfuzosin HCLPotential for hypotension.
AntiarrhythmicsAmiodarone, flecainide, propafenone, quinidinePotential for cardiac arrhythmias.
AntifungalVoriconazoleCoadministration of voriconazole with ritonavir 400 mg every 12 hours significantly decreases voriconazole plasma concentrations and may lead to loss of antifungal response. Voriconazole is contraindicated with ritonavir doses of 400 mg every 12 hours or greater [see Drug Interactions (7.2)].
Ergot DerivativesDihydroergotamine, ergonovine, ergotamine, methylergonovinePotential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.
GI Motility AgentCisapridePotential for cardiac arrhythmias.
Herbal ProductsSt. John's Wort (hypericum perforatum)May lead to loss of virologic response and possible resistance to NORVIR or to the class of protease inhibitors.
HMG-CoA Reductase Inhibitors:Lovastatin, simvastatinPotential for myopathy including rhabdomyolysis.
NeurolepticPimozidePotential for cardiac arrhythmias.
PDE5 enzyme inhibitorSildenafil* (Revatio®) only when used for the treatment of pulmonary arterial hypertension (PAH)A safe and effective dose has not been established when used with ritonavir. There is an increased potential for sildenafil-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope [see Drug Interactions (7)].
Sedative/hypnoticsOral midazolam, triazolamProlonged or increased sedation or respiratory depression [see Drug Interactions (7.2)].
*see Drug Interactions (7), Table 5 for coadministration of sildenafil in patients with erectile dysfunction.

** For additional information for these contraindicated drugs, see also Drug Interactions (7), Table 5.

Warnings and Precautions


When co-administering NORVIR with other protease inhibitors, see the full prescribing information for that protease inhibitor including important Warnings and Precautions.



Drug Interactions


NORVIR is a CYP3A inhibitor. Initiating treatment with NORVIR in patients receiving medications metabolized by CYP3A or initiating medications metabolized by CYP3A in patients already maintained on NORVIR may result in increased plasma concentrations of concomitant medications. Higher plasma concentrations of concomitant medications can result in increased or prolonged therapeutic or adverse effects, potentially leading to severe, life-threatening or fatal events. The potential for drug-drug interactions must be considered prior to and during therapy with NORVIR. Review of other medications taken by patients and monitoring of patients for adverse effects is recommended during therapy with NORVIR.


See Table 2 for a listing of drugs that are contraindicated with NORVIR due to potentially life-threatening adverse events, significant drug interactions, or loss of virologic activity. Also, see Table 5 for a listing of drugs with established and other significant drug interactions [see Contraindications (4) and Drug Interactions (7)].



Hepatic Reactions


Hepatic transaminase elevations exceeding 5 times the upper limit of normal, clinical hepatitis, and jaundice have occurred in patients receiving NORVIR alone or in combination with other antiretroviral drugs (see Table 4). There may be an increased risk for transaminase elevations in patients with underlying hepatitis B or C. Therefore, caution should be exercised when administering NORVIR to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Increased AST/ALT monitoring should be considered in these patients, especially during the first three months of NORVIR treatment [see Use In Specific Populations (8.6)].


There have been postmarketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients taking multiple concomitant medications and/or with advanced AIDS.



Pancreatitis


Pancreatitis has been observed in patients receiving NORVIR therapy, including those who developed hypertriglyceridemia. In some cases fatalities have been observed. Patients with advanced HIV disease may be at increased risk of elevated triglycerides and pancreatitis [see Warnings and Precautions (5.8)]. Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur. Patients who exhibit these signs or symptoms should be evaluated and NORVIR therapy should be discontinued if a diagnosis of pancreatitis is made.



Allergic Reactions/Hypersensitivity


Allergic reactions including urticaria, mild skin eruptions, bronchospasm, and angioedema have been reported. Cases of anaphylaxis, toxic epidermal necrolysis (TEN), and Stevens-Johnson syndrome have also been reported. Discontinue treatment if severe reactions develop.



PR Interval Prolongation


Ritonavir prolongs the PR interval in some patients. Post marketing cases of second or third degree atrioventricular block have been reported in patients.


NORVIR should be used with caution in patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, cardiomyopathies, as these patients may be at increased risk for developing cardiac conduction abnormalities.


The impact on the PR interval of co-administration of ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. As a result, co-administration of ritonavir with these drugs should be undertaken with caution, particularly with those drugs metabolized by CYP3A. Clinical monitoring is recommended. [see Clinical Pharmacology (12.3)].



Lipid Disorders


Treatment with NORVIR therapy alone or in combination with saquinavir has resulted in substantial increases in the concentration of total cholesterol and triglycerides [see Adverse Reactions (6.1)]. Triglyceride and cholesterol testing should be performed prior to initiating NORVIR therapy and at periodic intervals during therapy. Lipid disorders should be managed as clinically appropriate, taking into account any potential drug-drug interactions with NORVIR and HMG CoA reductase inhibitors [see Contraindications (4) and Drug Interactions (7)].



Diabetes Mellitus/Hyperglycemia


New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, and hyperglycemia have been reported during postmarketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established.



Immune Reconstitution Syndrome


Immune reconstitution syndrome has been reported in HIV-infected patients treated with combination antiretroviral therapy, including NORVIR. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveci pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.



Fat Redistribution


Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.



Patients with Hemophilia


There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in patients with hemophilia type A and B treated with protease inhibitors. In some patients additional factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced. A causal relationship between protease inhibitor therapy and these events has not been established.



Resistance/Cross-resistance


Varying degrees of cross-resistance among protease inhibitors have been observed. Continued administration of ritonavir 600 mg twice daily following loss of viral suppression may increase the likelihood of cross-resistance to other protease inhibitors [see Clinical Pharmacology (12.4)].



Laboratory Tests


Ritonavir has been shown to increase triglycerides, cholesterol, SGOT (AST), SGPT (ALT), GGT, CPK, and uric acid. Appropriate laboratory testing should be performed prior to initiating NORVIR therapy and at periodic intervals or if any clinical signs or symptoms occur during therapy. For comprehensive information concerning laboratory test alterations associated with reverse transcriptase inhibitors, physicians should refer to the complete product information for each of these drugs.



Adverse Reactions


The following adverse reactions are discussed in greater detail in other sections of the labeling.


  • Drug Interactions [see Warnings and Precautions (5.1)]

  • Hepatotoxicity [see Warnings and Precautions (5.2)]

  • Pancreatitis [see Warnings and Precautions (5.3)]

  • Allergic Reactions/Hypersensitivity [see Warnings and Precautions (5.4)]

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.


When co-administering NORVIR with other protease inhibitors, see the full prescribing information for that protease inhibitor including adverse reactions.



Adults — Clinical Trials Experience


The safety of NORVIR alone and in combination with nucleoside reverse transcriptase inhibitors was studied in 1270 adult patients. Table 3 lists treatment-emergent adverse events (at least possibly related and of at least moderate intensity) that occurred in 2% or greater of adult patients receiving NORVIR alone or in combination with nucleoside reverse transcriptase inhibitors in Study 245 or Study 247 and in combination with saquinavir in study 462. In that study, 141 protease inhibitor-naive, HIV-infected patients with mean baseline CD4 of 300 cells/μL were randomized to one of four regimens of NORVIR + saquinavir, including NORVIR 400 mg twice-daily + saquinavir 400 mg twice-daily. Overall the most frequently reported clinical adverse events, other than asthenia, among adult patients receiving NORVIR were gastrointestinal and neurological disturbances including nausea, diarrhea, vomiting, anorexia, abdominal pain, taste perversion, and circumoral and peripheral paresthesias. Similar adverse event profiles were reported in adult patients receiving ritonavir in other trials.















































































































































































































































































Table 3. Percentage of Patients with Treatment-emergent Adverse Events1 of Moderate or Severe Intensity Occurring in ≥ 2% of Adult Patients Receiving NORVIR
Adverse EventsStudy 245

Naive Patients2
Study 247

Advanced Patients3
Study 462

PI-Naive Patients4
 NORVIR + ZDV

n = 116
NORVIR

n = 117
ZDV

n = 119
NORVIR

n = 541
Placebo

n = 545
NORVIR + Saquinavir n= 141
Body as a Whole
    Abdominal Pain5.26.05.98.35.12.1
    Asthenia28.410.311.815.36.416.3
    Fever1.70.91.75.02.40.7
    Headache7.86.06.76.55.74.3
    Malaise5.21.73.40.70.22.8
    Pain (unspecified)0.91.70.82.21.84.3
Cardiovascular
    Syncope0.91.70.80.60.02.1
     Vasodilation3.41.70.81.70.03.5
Digestive
   Anorexia8.61.74.27.84.24.3
   Constipation3.40.00.80.20.41.4
   Diarrhea25.015.42.523.37.922.7
   Dyspepsia2.60.01.75.91.50.7
   Fecal Incontinence0.00.00.00.00.02.8
   Flatulence2.60.91.71.70.73.5
   Local Throat Irritation0.91.70.82.80.41.4
   Nausea46.625.626.129.88.418.4
   Vomiting23.313.712.617.44.47.1
Metabolic and Nutritional
   Weight Loss0.00.00.02.41.70.0
Musculoskeletal
   Arthralgia0.00.00.01.70.72.1
   Myalgia1.71.70.82.41.12.1
Nervous
   Anxiety0.90.00.81.70.92.1
   Circumoral Paresthesia5.23.40.06.70.46.4
   Confusion0.00.90.00.60.62.1
   Depression1.71.72.51.70.77.1
   Dizziness5.22.63.43.91.18.5
   Insomnia3.42.60.82.01.82.8
   Paresthesia5.22.60.03.00.42.1
   Peripheral Paresthesia0.06.00.85.01.15.7
   Somnolence2.62.60.02.40.20.0
   Thinking Abnormal2.60.00.80.90.40.7
Respiratory
   Pharyngitis0.92.60.00.40.41.4
Skin and Appendages
   Rash0.90.00.83.51.50.7
   Sweating3.42.61.71.71.12.8
Special Senses
   Taste Perversion17.211.18.47.02.25.0
Urogenital
   Nocturia0.00.00.00.20.02.8
1   Includes those adverse events at least possibly related to study drug or of unknown relationship and excludes concurrent HIV conditions.

2   The median duration of treatment for patients randomized to regimens containing NORVIR in Study 245 was 9.1 months.

3   The median duration of treatment for patients randomized to regimens containing NORVIR in Study 247 was 9.4 months.

4   The median duration of treatment for patients in Study 462 was 48 weeks.

Adverse events occurring in less than 2% of adult patients receiving NORVIR in all phase II/phase III studies and considered at least possibly related or of unknown relationship to treatment and of at least moderate intensity are listed below by body system.


Body as a Whole

Abdomen enlarged, accidental injury, allergic reaction, back pain, cachexia, chest pain, chills, facial edema, facial pain, flu syndrome, hormone level altered, hypothermia, kidney pain, neck pain, neck rigidity, pelvic pain, photosensitivity reaction, and substernal chest pain.


Cardiovascular System

Cardiovascular disorder, cerebral ischemia, cerebral venous thrombosis, hypertension, hypotension, migraine, myocardial infarct, palpitation, peripheral vascular disorder, phlebitis, postural hypotension, tachycardia and vasospasm.


Digestive System

Abnormal stools, bloody diarrhea, cheilitis, cholestatic jaundice, colitis, dry mouth, dysphagia, eructation, esophageal ulcer, esophagitis, gastritis, gastroenteritis, gastrointestinal disorder, gastrointestinal hemorrhage, gingivitis, hepatic coma, hepatitis, hepatomegaly, hepatosplenomegaly, ileus, liver damage, melena, mouth ulcer, pancreatitis, pseudomembranous colitis, rectal disorder, rectal hemorrhage, sialadenitis, stomatitis, tenesmus, thirst, tongue edema, and ulcerative colitis.


Endocrine System

Adrenal cortex insufficiency and diabetes mellitus.


Hemic and Lymphatic System

Acute myeloblastic leukemia, anemia, ecchymosis, leukopenia, lymphadenopathy, lymphocytosis, myeloproliferative disorder, and thrombocytopenia.


Metabolic and Nutritional Disorders

Albuminuria, alcohol intolerance, avitaminosis, BUN increased, dehydration, edema, enzymatic abnormality, glycosuria, gout, hypercholesteremia, peripheral edema, and xanthomatosis.


Musculoskeletal System

Arthritis, arthrosis, bone disorder, bone pain, extraocular palsy, joint disorder, leg cramps, muscle cramps, muscle weakness, myositis, and twitching.


Nervous System

Abnormal dreams, abnormal gait, agitation, amnesia, aphasia, ataxia, coma, convulsion, dementia, depersonalization, diplopia, emotional lability, euphoria, grand mal convulsion, hallucinations, hyperesthesia, hyperkinesia, hypesthesia, incoordination, libido decreased, manic reaction, nervousness, neuralgia, neuropathy, paralysis, peripheral neuropathic pain, peripheral neuropathy, peripheral sensory neuropathy, personality disorder, sleep disorder, speech disorder, stupor, subdural hematoma, tremor, urinary retention, vertigo, and vestibular disorder.


Respiratory System

Asthma, bronchitis, dyspnea, epistaxis, hiccup, hypoventilation, increased cough, interstitial pneumonia, larynx edema, lung disorder, rhinitis, and sinusitis.


Skin and Appendages

Acne, contact dermatitis, dry skin, eczema, erythema multiforme, exfoliative dermatitis, folliculitis, fungal dermatitis, furunculosis, maculopapular rash, molluscum contagiosum, onychomycosis, pruritus, psoriasis, pustular rash, seborrhea, skin discoloration, skin disorder, skin hypertrophy, skin melanoma, urticaria, and vesiculobullous rash.


Special Senses

Abnormal electro-oculogram, abnormal electroretinogram, abnormal vision, amblyopia/blurred vision, blepharitis, conjunctivitis, ear pain, eye disorder, eye pain, hearing impairment, increased cerumen, iritis, parosmia, photophobia, taste loss, tinnitus, uveitis, visual field defect, and vitreous disorder.


Urogenital System

Acute kidney failure, breast pain, cystitis, dysuria, hematuria, impotence, kidney calculus, kidney failure, kidney function abnormal, kidney pain, menorrhagia, penis disorder, polyuria, urethritis, urinary frequency, urinary tract infection, and vaginitis.



Laboratory Abnormalities


Table 4 shows the percentage of adult patients who developed marked laboratory abnormalities.


















































































































































Table 4. Percentage of Adult Patients, by Study and Treatment Group, with Chemistry and Hematology Abnormalities Occurring in > 3% of Patients Receiving NORVIR
  Study 245

Naive Patients
Study 247

Advanced Patients
Study 462 PI-Naive Patients
VariableLimitNORVIR + ZDVNORVIRZDVNORVIRPlaceboNORVIR + Saquinavir
ChemistryHigh      
Cholesterol> 240 mg/dL30.744.89.336.58.065.2
CPK> 1000 IU/L9.612.111.09.16.39.9
GGT> 300 IU/L1.85.21.719.611.39.2
SGOT (AST)> 180 IU/L5.39.52.56.47.07.8
SGPT (ALT)> 215 IU/L5.37.83.48.54.49.2
Triglycerides> 800 mg/dL9.617.23.433.69.423.4
Triglycerides> 1500 mg/dL1.82.6-12.60.411.3
Triglycerides Fasting> 1500 mg/dL1.51.3-9.90.3-
Uric Acid> 12 mg/dL---3.80.21.4
HematologyLow      
Hematocrit< 30%2.6-0.817.322.00.7
Hemoglobin< 8.0 g/dL0.9--3.83.9-
Neutrophils≤ 0.5 x 109/L---6.08.3-
RBC< 3.0 x 1012/L1.8-5.918.624.4-
WBC< 2.5 x 109/L-0.96.836.959.43.5
-   Indicates no events reported.

Pediatrics - Treatment-Emergent Adverse Events


NORVIR has been studied in 265 pediatric patients > 1 month to 21 years of age. The adverse event profile observed during pediatric clinical trials was similar to that for adult patients.


Vomiting, diarrhea, and skin rash/allergy were the only drug-related clinical adverse events of moderate to severe intensity observed in ≥ 2% of pediatric patients enrolled in NORVIR clinical trials.


Laboratory Abnormalities

The following Grade 3-4 laboratory abnormalities occurred in > 3% of pediatric patients who received treatment with NORVIR either alone or in combination with reverse transcriptase inhibitors: neutropenia (9%), hyperamylasemia (7%), thrombocytopenia (5%), anemia (4%), and elevated AST (3%).



Postmarketing Experience


The following adverse events (not previously mentioned in the labeling) have been reported during post-marketing use of NORVIR. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to NORVIR exposure.


Body as a Whole

Dehydration, usually associated with gastrointestinal symptoms, and sometimes resulting in hypotension, or renal insufficiency has been reported. Syncope, orthostatic hypotension, and renal insufficiency have also been reported without known dehydration.


Co-administration of ritonavir with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.


Cardiovascular System

First – degree AV block, second-degree AV block, third-degree AV block, right bundle branch block have been reported [see Warnings and Precautions (5.5)].


Cardiac and neurologic events have been reported when ritonavir has been co-administered with disopyramide, mexiletine, nefazodone, fluoxetine, and beta blockers. The possibility of drug interaction cannot be excluded.


Endocrine System

Cushing's syndrome and adrenal suppression have been reported when ritonavir has been co-administered with fluticasone propionate.


Nervous System

There have been postmarketing reports of seizure. Also, see Cardiovascular System.


Skin and subcutaneous tissue disorders

Toxic epidermal necrolysis (TEN) has been reported.



Drug Interactions


See also Contraindications (4), Clinical Pharmacology (12.3)


When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.



Potential for NORVIR to Affect Other Drugs


Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to

Monday, 20 August 2012

Tranylcypromine





Dosage Form: tablet

SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Tranylcypromine sulfate or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Tranylcypromine sulfate is not approved for use in pediatric patients. (See WARNINGS TO PHYSICIANS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)




Tranylcypromine Description


Chemically, Tranylcypromine sulfate is (±)-trans-2-phenylcyclopropylamine sulfate (2:1).


Each round, dark pink, film-coated tablet is debossed with “250” on one side and “K” on the other side and contains Tranylcypromine sulfate equivalent to 10 mg of Tranylcypromine. Inactive ingredients consist of colloidal silicon dioxide, croscarmellose sodium, dibasic calcium phosphate anhydrous, magnesium stearate, microcrystalline cellulose, talc, and Opadry® II pink 85F14289. Opadry pink is used for purposes of coating and contains the following: FD&C Red # 40, polyethylene glycol 3350, polyvinyl alcohol, talc, and titanium dioxide.



ACTION


Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. It increases the concentration of epinephrine, norepinephrine, and serotonin in storage sites throughout the nervous system and, in theory, this increased concentration of monoamines in the brain stem is the basis for its antidepressant activity. When Tranylcypromine is withdrawn, monoamine oxidase activity is recovered in 3 to 5 days, although the drug is excreted in 24 hours.



INDICATIONS


For the treatment of Major Depressive Episode Without Melancholia.


Tranylcypromine sulfate should be used in adult patients who can be closely supervised. It should rarely be the first antidepressant drug given. Rather, the drug is suited for patients who have failed to respond to the drugs more commonly administered for depression.


The effectiveness of Tranylcypromine sulfate has been established in adult outpatients, most of whom had a depressive illness which would correspond to a diagnosis of Major Depressive Episode Without Melancholia. As described in the American Psychiatric Association's Diagnostic and Statistical Manual, third edition (DSM III), Major Depressive Episode implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning and includes at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts.


The effectiveness of Tranylcypromine sulfate in patients who meet the criteria for Major Depressive Episode with Melancholia (endogenous features) has not been established.



SUMMARY OF CONTRAINDICATIONS


Tranylcypromine sulfate should not be administered in combination with any of the following: MAO inhibitors or dibenzazepine derivatives; sympathomimetics (including amphetamines); some central nervous system depressants (including narcotics and alcohol); antihypertensive, diuretic, antihistaminic, sedative, or anesthetic drugs; bupropion HCl; buspirone HCI; dextromethorphan; cheese or other foods with a high tyramine content; or excessive quantities of caffeine.


Tranylcypromine sulfate should not be administered to any patient with a confirmed or suspected cerebrovascular defect or to any patient with cardiovascular disease, hypertension, or history of headache.


(For complete discussion of contraindications and warnings, see below.)



Contraindications


Tranylcypromine sulfate is contraindicated:


1. In patients with cerebrovascular defects or cardiovascular disorders


Tranylcypromine sulfate should not be administered to any patient with a confirmed or suspected cerebrovascular defect or to any patient with cardiovascular disease or hypertension.


2. In the presence of pheochromocytoma


Tranylcypromine sulfate should not be used in the presence of pheochromocytoma since such tumors secrete pressor substances.


3. In combination with MAO inhibitors or with dibenzazepine-related entities


Tranylcypromine sulfate should not be administered together or in rapid succession with other MAO inhibitors or with dibenzazepine-related entities. Hypertensive crises or severe convulsive seizures may occur in patients receiving such combinations.


In patients being transferred to Tranylcypromine sulfate from another MAO inhibitor or from a dibenzazepine-related entity, allow a medication-free interval of at least a week, then initiate Tranylcypromine sulfate using half the normal starting dosage for at least the first week of therapy. Similarly, at least a week should elapse between the discontinuance of Tranylcypromine sulfate and the administration of another MAO inhibitor or a dibenzazepine-related entity, or the readministration of Tranylcypromine sulfate.


The following list includes some other MAO inhibitors, dibenzazepine-related entities and tricyclic antidepressants, and the companies which market them.



















Other MAO Inhibitors
Generic NameSource
Furazolidone
IsocarboxazidMarplan® (Oxford Pharm Services)
Pargyline HCl
Pargyline HCl and methyclothiazide
Phenelzine sulfateNardil® (Pfizer)
Procarbazine HClMatulane® (Sigma Tau)






































Dibenzazepine-Related and Other Tricyclics
Generic NameSource
Amitriptyline HCl(Sandoz)
Perphenazine and amitriptyline HCl(Sandoz)
Clomipramine hydrochlorideAnafranil® (Mallinckrodt)
Desipramine HCl(Sandoz)
Imipramine HCl(Sandoz)
Tofranil® (Mallinckrodt) 
Nortriptyline HCl(Mylan)
Pamelor® (Mallinckrodt) 
Protriptyline HClVivactil® (Odyssey Pharmaceuticals, Inc.)
Doxepin HClSinequan® (Pfizer)
CarbamazepineTegretol® (Novartis)
Cyclobenzaprine HCl(Mylan)
Flexeril® (McNeil) 
Amoxapine(Watson)
Maprotiline HCl(Mylan)
Trimipramine maleateSurmontil® (Odyssey Pharmaceuticals, Inc.)

4. In combination with bupropion


The concurrent administration of an MAO inhibitor and bupropion hydrochloride (Wellbutrin®, Wellbutrin SR®, Wellbutrin XL®, Zyban®, GlaxoSmithKline) is contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with bupropion hydrochloride.


5.In combination with selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs)


As a general rule, Tranylcypromine sulfate should not be administered in combination with any SSRI. There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving a SSRI (e.g., fluoxetine (Prozac®, Eli Lilly and Company) or a SNRI (e.g., venlafaxine, Effexor®, Effexor XR®, Wyeth) in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued a SSRI or SNRI and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, SSRI’s and SNRI should not be used in combination with an MAOI, or within 14 days of discontinuing therapy with an MAOI.


Since fluoxetine and its major metabolite have very long elimination half-lives, at least 5 weeks should be allowed after stopping fluoxetine before starting an MAOI.


At least 2 weeks should be allowed after stopping sertraline (Zoloft®, Pfizer) or paroxetine (Paxil®, GlaxoSmithKline) before starting an MAOI.


At least one week should be allowed after stopping a SNRI (e.g., venlafaxine) before starting a MAOI.


6. In combination with buspirone


Tranylcypromine sulfate should not be used in combination with buspirone HCl, since several cases of elevated blood pressure have been reported in patients taking MAO inhibitors who were then given buspirone HCl. At least 10 days should elapse between the discontinuation of Tranylcypromine sulfate and the institution of buspirone HCl.


7. In combination with sympathomimetics


Tranylcypromine sulfate should not be administered in combination with sympathomimetics, including amphetamines, which may be found in many herbal preparations as well as over-the-counter drugs such as cold, hay fever or weight-reducing preparations that contain vasoconstrictors.


During therapy with Tranylcypromine sulfate, it appears that certain patients are particularly vulnerable to the effects of sympathomimetics when the activity of certain enzymes is inhibited. Use of sympathomimetics and compounds such as guanethidine, methyldopa, reserpine, dopamine, levodopa, and tryptophan with Tranylcypromine sulfate may precipitate hypertension, headache, and related symptoms. . Cerebral hemorrhage may also occur. The combination of MAOIs and tryptophan has been reported to cause behavioral and neurologic syndromes including disorientation, confusion, amnesia, delirium, agitation, hypomanic signs, ataxia, myoclonus, hyperreflexia, shivering, ocular oscillations, and Babinski's signs.


8. In combination with meperidine


Do not use meperidine concomitantly with MAO inhibitors or within 2 or 3 weeks following MAOI therapy. Serious reactions have been precipitated with concomitant use, including coma, severe hypertension or hypotension, severe respiratory depression, convulsions, malignant hyperpyrexia, excitation, peripheral vascular collapse, and death. It is thought that these reactions may be mediated by accumulation of 5-HT (serotonin) consequent to MAO inhibition.


9. In combination with dextromethorphan


The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior.


10. In combination with cheese or other foods with a high tyramine content


When excessive amounts of tyramine are consumed in conjunction with Tranylcypromine, or within 2 weeks of stopping treatment, a serious and sometimes fatal hypertensive reaction may occur.


Tyramine occurs naturally in some foods or may occur from the bacterial breakdown of protein in foods which are fermented, aged, or spoiled. Foods that have reliably been shown to contain a high tyramine content and may also have been reported to induce a serious hypertensive reaction when consumed with Tranylcypromine are:


  • all matured or aged cheeses (note: all cheeses are considered matured or aged except fresh cottage cheese, cream cheese, ricotta, and processed cheese. All non-cheese dairy products can be consumed providing they are fresh)

  • all aged, cured or fermented meat, fish, or poultry (note: meat, fish, or poultry that has not undergone aging, curing or fermenting and that is bought fresh, stored correctly and eaten fresh is not contraindicated)

  • all fermented soybean products (e.g., soy sauce, miso, fermented tofu)

  • sauerkraut

  • fava or broad bean pods

  • banana peel (but not the pulp)

  • concentrated yeast extracts (e.g., Marmite or Vegemite spread)

  • all tap/draught beers (note: some bottled beers, including non-alcoholic beer, may also pose a risk).

Patients should be advised to minimize or avoid use of all alcoholic beverages while taking Tranylcypromine sulfate. Patients should be advised to adhere to the following dietary guidance about eating fresh foods:


Foods may be deliberately aged as part of their processing and these are contraindicated (see list above). Foods may also naturally age over time, even if they are refrigerated. It is therefore extremely important that patients are instructed to buy and eat only fresh foods or those which have been properly frozen. They should avoid eating foods if they are unsure of their storage conditions or freshness and they should be cautious of foods of unknown age or composition even if refrigerated.


The longer food is left to deteriorate and the larger the quantity of food eaten, the greater the potential quantity of tyramine ingested. Where there is any doubt, patients should be advised to either avoid the food or consume it in strict moderation if it is not otherwise contraindicated.


Patients should also be warned that tyramine levels may vary by brand or even batch and a person may absorb different amounts of tyramine from a particular food at different times. Therefore, if they have accidentally consumed a prohibited food on one occasion and not had a reaction, this does not mean that they will not have a serious hypertensive reaction if they consume the same food on a different occasion.


11. In patients undergoing elective surgery


Patients taking Tranylcypromine sulfate should not undergo elective surgery requiring general anesthesia. Also, they should not be given cocaine or local anesthesia containing sympathomimetic vasoconstrictors. The possible combined hypotensive effects of Tranylcypromine sulfate and spinal anesthesia should be kept in mind. Tranylcypromine sulfate should be discontinued at least 10 days prior to elective surgery.



ADDITIONAL CONTRAINDICATIONS


In general, the physician should bear in mind the possibility of a lowered margin of safety when Tranylcypromine sulfate is administered in combination with potent drugs.


  1. Tranylcypromine sulfate should not be used in combination with some central nervous system depressants such as narcotics and alcohol, or with hypotensive agents. A marked potentiating effect on these classes of drugs has been reported.

  2. Anti-parkinsonism drugs should be used with caution in patients receiving Tranylcypromine sulfate since severe reactions have been reported.

  3. Tranylcypromine sulfate should not be used in patients with a history of liver disease or in those with abnormal liver function tests.

  4. Excessive use of caffeine in any form should be avoided in patients receiving Tranylcypromine sulfate.


WARNINGS TO PHYSICIANS



Clinical Worsening and Suicide Risk:


Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.


The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.
















Table 1
Age RangeDrug-Placebo Difference in Number of Cases of Suicidality per 1,000 Patients Treated
Increases Compared to Placebo
<1814 additional cases
18 to 245 additional cases
Decreases Compared to Placebo
25 to 641 fewer case
>656 fewer cases

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.


It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.


All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.


The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.


Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.


Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Tranylcypromine sulfate should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.



Screening Patients for Bipolar Disorder:


A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that Tranylcypromine sulfate is not approved for use in treating bipolar depression.


Tranylcypromine sulfate is a potent agent with the capability of producing serious side effects. Tranylcypromine sulfate is not recommended in those depressive reactions where other antidepressant drugs may be effective. It should be reserved for patients who can be closely supervised and who have not responded satisfactorily to the drugs more commonly administered for depression.


Before prescribing, the physician should be completely familiar with the full material on dosage, side effects, and contraindications on these pages, with the principles of MAO inhibitor therapy and the side effects of this class of drugs. Also, the physician should be familiar with the symptomatology of mental depressions and alternate methods of treatment to aid in the careful selection of patients for therapy with Tranylcypromine sulfate.



Pregnancy Warning:


Use of any drug in pregnancy, during lactation or in women of childbearing age requires that the potential benefits of the drug be weighed against its possible hazards to mother and child.


Animal reproductive studies show that Tranylcypromine sulfate passes through the placental barrier into the fetus of the rat, and into the milk of the lactating dog. The absence of a harmful action of Tranylcypromine sulfate on fertility or on postnatal development by either prenatal treatment or from the milk of treated animals has not been demonstrated. Tranylcypromine is excreted in human milk.



WARNING TO THE PATIENT


Patients should be instructed to report promptly the occurrence of headache or other unusual symptoms, i.e., palpitation and/or tachycardia, a sense of constriction in the throat or chest, sweating, dizziness, neck stiffness, nausea, or vomiting.


Patients should be warned against eating the foods listed in Section 11 under CONTRAINDICATIONS while on therapy with Tranylcypromine sulfate. Also, they should be told not to drink alcoholic beverages. The patient should also be warned about the possibility of hypotension and faintness, as well as drowsiness sufficient to impair performance of potentially hazardous tasks such as driving a car or operating machinery.


Patients should also be cautioned not to take concomitant medications, whether prescription or over-the-counter drugs such as cold, hay fever, or weight-reducing preparations, without the advice of a physician. They should be advised not to consume excessive amounts of caffeine in any form. Likewise, they should inform other physicians, and their dentist, about their use of Tranylcypromine sulfate.


See PRECAUTIONS -Information for Patients for information regarding clinical worsening and suicide risk.



Warnings



Hypertensive Crisis:


The most important reaction associated with Tranylcypromine sulfate is the occurrence of hypertensive crises which have sometimes been fatal.


These crises are characterized by some or all of the following symptoms: occipital headache which may radiate frontally, palpitation, neck stiffness or soreness, nausea or vomiting, sweating (sometimes with fever and sometimes with cold, clammy skin) and photophobia. Either tachycardia or bradycardia may be present, and associated constricting chest pain and dilated pupils may occur. Intracranial bleeding, sometimes fatal in outcome, has been reported in association with the paradoxical increase in blood pressure.


In all patients taking Tranylcypromine sulfate, blood pressure should be followed closely to detect evidence of any pressor response. It is emphasized that full reliance should not be placed on blood pressure readings, but that the patient should also be observed frequently.


Therapy should be discontinued immediately upon the occurrence of palpitation or frequent headaches during therapy with Tranylcypromine sulfate. These signs may be prodromal of a hypertensive crisis.



Important:


Recommended treatment in hypertensive crises


If a hypertensive crisis occurs, Tranylcypromine sulfate should be discontinued and therapy to lower blood pressure should be instituted immediately. Headache tends to abate as blood pressure is lowered. On the basis of present evidence, phentolamine is recommended. (The dosage reported for phentolamine is 5 mg I.V.) Care should be taken to administer this drug slowly in order to avoid producing an excessive hypotensive effect. Fever should be managed by means of external cooling. Other symptomatic and supportive measures may be desirable in particular cases. Do not use parenteral reserpine.



Precautions



Hypotension:


Hypotension has been observed during therapy with Tranylcypromine sulfate. Symptoms of postural hypotension are seen most commonly but not exclusively in patients with pre-existent hypertension; blood pressure usually returns rapidly to pretreatment levels upon discontinuation of the drug. At doses above 30 mg daily, postural hypotension is a major side effect and may result in syncope. Dosage increases should be made more gradually in patients showing a tendency toward hypotension at the beginning of therapy. Postural hypotension may be relieved by having the patient lie down until blood pressure returns to normal.


Also, when Tranylcypromine sulfate is combined with those phenothiazine derivatives or other compounds known to cause hypotension, the possibility of additive hypotensive effects should be considered.


There have been reports of drug dependency in patients using doses of Tranylcypromine significantly in excess of the therapeutic range. Some of these patients had a history of previous substance abuse. The following withdrawal symptoms have been reported: restlessness, anxiety, depression, confusion, hallucinations, headache, weakness, and diarrhea.


Drugs which lower the seizure threshold, including MAO inhibitors, should not be used with Amipaque®*. As with other MAO inhibitors, Tranylcypromine sulfate should be discontinued at least 48 hours before myelography and should not be resumed for at least 24 hours post-procedure.


MAO inhibitors may have the capacity to suppress anginal pain that would otherwise serve as a warning of myocardial ischemia.


The usual precautions should be observed in patients with impaired renal function since there is a possibility of cumulative effects in such patients.


Older patients may suffer more morbidity than younger patients during and following an episode of hypertension or malignant hyperthermia. Older patients have less compensatory reserve to cope with any serious adverse reaction. Therefore, Tranylcypromine sulfate should be used with caution in the elderly population.


Although excretion of Tranylcypromine sulfate is rapid, inhibition of MAO may persist up to 10 days following discontinuation.


Because the influence of Tranylcypromine sulfate on the convulsive threshold is variable in animal experiments, suitable precautions should be taken if epileptic patients are treated.


Some MAO inhibitors have contributed to hypoglycemic episodes in diabetic patients receiving insulin or oral hypoglycemic agents. Therefore, Tranylcypromine sulfate should be used with caution in diabetics using these drugs.


Tranylcypromine sulfate may aggravate coexisting symptoms in depression, such as anxiety and agitation.


Use Tranylcypromine sulfate with caution in hyperthyroid patients because of their increased sensitivity to pressor amines.


Tranylcypromine sulfate should be administered with caution to patients receiving Antabuse®†. In a single study, rats given high intraperitoneal doses of d or l isomers of Tranylcypromine sulfate plus disulfiram experienced severe toxicity including convulsions and death. Additional studies in rats given high oral doses of racemic Tranylcypromine sulfate and disulfiram produced no adverse interaction.



Information for Patients:


Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Tranylcypromine sulfate and should counsel them in its appropriate use. A patient Medication Guide about “Antidepressant Medicines, Depression and Other Serious Mental Illness, and Suicidal Thoughts or Actions” is available for Tranylcypromine sulfate. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.


Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Tranylcypromine sulfate.



Clinical Worsening and Suicide Risk:


Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.



Pediatric Use:


Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and WARNINGS TO PHYSICIANS - Clinical Worsening and Suicide Risk). Anyone considering the use of Tranylcypromine sulfate in a child or adolescent must balance the potential risks with the clinical need.



Adverse Reactions


Overstimulation which may include increased anxiety, agitation, and manic symptoms is usually evidence of excessive therapeutic action. Dosage should be reduced, or a phenothiazine tranquilizer should be administered concomitantly.


Patients may experience restlessness or insomnia; may notice some weakness, drowsiness, episodes of dizziness or dry mouth; or may report nausea, diarrhea, abdominal pain, or constipation. Most of these effects can be relieved by lowering the dosage or by giving suitable concomitant medication.


Tachycardia, significant anorexia, edema, palpitation, blurred vision, chills, and impotence have each been reported.


Headaches without blood pressure elevation have occurred.


Rare instances of hepatitis, skin rash, and alopecia have been reported.


Impaired water excretion compatible with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) has been reported.


Tinnitus, muscle spasm, tremors, myoclonic jerks, numbness, paresthesia, urinary retention, and retarded ejaculation have been reported.


Hematologic disorders including anemia, leukopenia, agranulocytosis, and thrombocytopenia have been reported.



Post-Introduction Reports


The following are spontaneously reported adverse events temporally associated with use of Tranylcypromine sulfate. No clear relationship between Tranylcypromine sulfate and these events has been established. Localized scleroderma, flare-up of cystic acne, ataxia, confusion, disorientation, memory loss, urinary frequency, urinary incontinence, urticaria, fissuring in corner of mouth, akinesia.



Tranylcypromine Dosage and Administration


Dosage should be adjusted to the requirements of the individual patient. Improvement should be seen within 48 hours to 3 weeks after starting therapy.


The usual effective dosage is 30 mg per day, usually given in divided doses. If there are no signs of improvement after a reasonable period (up to 2 weeks), then the dosage may be increased in 10 mg per day increments at intervals of 1 to 3 weeks; the dosage range may be extended to a maximum of 60 mg per day from the usual 30 mg per day.



Overdosage



Symptoms:


The characteristic symptoms that may be caused by overdosage are usually those described above.


However, an intensification of these symptoms and sometimes severe additional manifestations may be seen, depending on the degree of overdosage and on individual susceptibility. Some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion, and incoherence. Hypotension, dizziness, weakness, and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.



Treatment:


Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug. Telephone numbers for the certified Poison Control Centers are listed in the Physicians’ Desk Reference (PDR).


Treatment should normally consist of general supportive measures, close observation of vital signs and steps to counteract specific symptoms as they occur, since MAO inhibition may persist. The management of hypertensive crises is described under WARNINGS in the Hypertensive Crisis section.


External cooling is recommended if hyperpyrexia occurs. Barbiturates have been reported to help relieve myoclonic reactions, but frequency of administration should be controlled carefully because Tranylcypromine sulfate may prolong barbiturate activity. When hypotension requires treatment, the standard measures for managing circulatory shock should be initiated. If pressor agents are used, the rate of infusion should be regulated by careful observation of the patient because an exaggerated pressor response sometimes occurs in the presence of MAO inhibition. Remember that the toxic effect of Tranylcypromine sulfate may be delayed or prolonged following the last dose of the drug. Therefore, the patient should be closely observed for at least a week. It is not known if Tranylcypromine is dialyzable.



How is Tranylcypromine Supplied


Tranylcypromine Sulfate Tablets, USP are supplied as round, dark pink, film-coated tablets debossed with “250” on one side and “K” on the other side and contains Tranylcypromine sulfate equivalent to 10 mg of Tranylcypromine, in bottles of 100 with a desiccant.


10 mg 100's: NDC 49884-032-01


Store at 20º to 25ºC (68º to 77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF).


[See USP Controlled Room Temperature].


* metrizamide, The Sanofi-Aventis Group


† disulfiram, Odyssey Pharmaceuticals, Inc.



MEDICATION GUIDE


Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions


Tranylcypromine Sulfate Tablets, USP


Read the Medication Guide that comes with your or your family member’s antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. Talk to your, or your family member’s, healthcare provider about:


  • All risks and benefits of treatment with antidepressant medicines

  • All treatment choices for depression or other serious mental illness

What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?


Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.


Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high r

Friday, 17 August 2012

Pred-Ject-50


Generic Name: prednisolone (pred NIS oh lone)

Brand Names: Bubbli-Pred, Flo-Pred, Hydeltrasol, Key-Pred SP, Millipred, Orapred, Orapred ODT, Pediapred, Pred-Ject-50, Predacort 50, Predalone 50, Predate-50, Veripred 20


What is Pred-Ject-50 (prednisolone)?

Prednisolone is in a class of drugs called steroids. Prednisolone prevents the release of substances in the body that cause inflammation.


Prednisolone is used to treat many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.


Prednisolone may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Pred-Ject-50 (prednisolone)?


You should not use this medication if you are allergic to prednisolone, or if you have a fungal infection anywhere in your body.

Before taking prednisolone, tell your doctor about all of your medical conditions, and about all other medicines you are using. There are many other diseases that can be affected by steroid use, and many other medicines that can interact with steroids.


Your steroid medication needs may change if you have any unusual stress such as a serious illness, fever or infection, or if you have surgery or a medical emergency. Tell your doctor about any such situation that affects you during treatment.


Steroid medication can weaken your immune system, making it easier for you to get an infection or worsening an infection you already have or have recently had. Tell your doctor about any illness or infection you have had within the past several weeks.


Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medication.


Do not receive a "live" vaccine while you are taking prednisolone. Vaccines may not work as well while you are taking a steroid.


Do not stop using prednisolone suddenly, or you could have unpleasant withdrawal symptoms. Talk to your doctor about how to avoid withdrawal symptoms when stopping the medication. Carry an ID card or wear a medical alert bracelet stating that you are taking a steroid, in case of emergency.

What should I discuss with my healthcare provider before taking Pred-Ject-50 (prednisolone)?


You should not use this medication if you are allergic to prednisolone, or if you have a fungal infection anywhere in your body.

Steroid medication can weaken your immune system, making it easier for you to get an infection. Steroids can also worsen an infection you already have, or reactivate an infection you recently had. Before taking this medication, tell your doctor about any illness or infection you have had within the past several weeks.


If you have any of these other conditions, you may need a dose adjustment or special tests to safely use this medication:



  • liver disease (such as cirrhosis);




  • kidney disease;




  • a thyroid disorder;




  • diabetes;




  • a history of malaria;




  • tuberculosis;




  • osteoporosis;




  • a muscle disorder such as myasthenia gravis;




  • glaucoma or cataracts;




  • herpes infection of the eyes;




  • stomach ulcers, ulcerative colitis, or diverticulitis;




  • depression or mental illness;




  • congestive heart failure; or




  • high blood pressure




FDA pregnancy category C. It is not known whether prednisolone is harmful to an unborn baby. Before taking this medication, tell your doctor if you are pregnant or plan to become pregnant during treatment. Prednisolone can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Steroids can affect growth in children. Talk with your doctor if you think your child is not growing at a normal rate while using this medication.

How should I take Pred-Ject-50 (prednisolone)?


Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.


Your doctor may occasionally change your dose to make sure you get the best results from this medication.


Your steroid medication needs may change if you have unusual stress such as a serious illness, fever or infection, or if you have surgery or a medical emergency. Tell your doctor about any such situation that affects you.


Measure the liquid form of prednisolone with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Keep the disintegrating tablet (Orapred ODT) in its blister pack until you are ready to take the medicine. Open the package using dry hands, and peel back the foil from the tablet blister (do not push the tablet through the foil). Remove the tablet and place it in your mouth.


Allow the disintegrating tablet to dissolve in your mouth without chewing. Swallow several times as the tablet dissolves. If desired, you may drink liquid to help swallow the dissolved tablet.


Steroids can cause you to have unusual results with certain medical tests. Tell any doctor who treats you that you are using prednisolone.


Do not stop using prednisolone suddenly, or you could have unpleasant withdrawal symptoms. Talk to your doctor about how to avoid withdrawal symptoms when stopping the medication. Carry an ID card or wear a medical alert bracelet stating that you are taking a steroid, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are taking steroid medication. Store prednisolone at room temperature away from moisture and heat.

What happens if I miss a dose?


If you miss a dose or forget to take your medicine, contact your doctor or pharmacist for instructions.


What happens if I overdose?


Seek emergency medical attention if you think you have received too much of this medicine.

A single large dose of prednisolone is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.


What should I avoid while taking Pred-Ject-50 (prednisolone)?


Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medication.


Do not receive a "live" vaccine while you are being treated with prednisolone. Vaccines may not work as well while you are taking a steroid.


Avoid drinking alcohol while you are taking prednisolone.

Pred-Ject-50 (prednisolone) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

  • problems with your vision;




  • swelling, rapid weight gain, feeling short of breath;




  • severe depression, unusual thoughts or behavior, seizure (convulsions);




  • bloody or tarry stools, coughing up blood;




  • pancreatitis (severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate);




  • low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling); or




  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).



Less serious side effects may include:



  • sleep problems (insomnia), mood changes;




  • acne, dry skin, thinning skin, bruising or discoloration;




  • slow wound healing;




  • increased sweating;




  • headache, dizziness, spinning sensation;




  • nausea, stomach pain, bloating; or




  • changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Pred-Ject-50 (prednisolone)?


There are many other medicines that can interact with steroids. Below is only a partial list of these medicines:



  • aspirin (taken on a daily basis or at high doses);




  • a diuretic (water pill);




  • a blood thinner such as warfarin (Coumadin);




  • cyclosporine (Gengraf, Neoral, Sandimmune);




  • insulin or diabetes medications you take by mouth;




  • ketoconazole (Nizoral);




  • rifampin (Rifadin, Rifater, Rifamate, Rimactane); or




  • seizure medications such as phenytoin (Dilantin) or phenobarbital (Luminal, Solfoton).



This list is not complete and there may be other drugs that can interact with prednisolone. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More Pred-Ject-50 resources


  • Pred-Ject-50 Side Effects (in more detail)
  • Pred-Ject-50 Use in Pregnancy & Breastfeeding
  • Pred-Ject-50 Drug Interactions
  • Pred-Ject-50 Support Group
  • 0 Reviews for Pred-Ject-50 - Add your own review/rating


  • Bubbli-Pred Advanced Consumer (Micromedex) - Includes Dosage Information

  • Flo-Pred Prescribing Information (FDA)

  • Flo-Pred Consumer Overview

  • Flo-Pred Suspension MedFacts Consumer Leaflet (Wolters Kluwer)

  • Millipred Prescribing Information (FDA)

  • Millipred DP MedFacts Consumer Leaflet (Wolters Kluwer)

  • Orapred Solution MedFacts Consumer Leaflet (Wolters Kluwer)

  • Orapred Prescribing Information (FDA)

  • Orapred Consumer Overview

  • Orapred ODT Prescribing Information (FDA)

  • Orapred ODT MedFacts Consumer Leaflet (Wolters Kluwer)

  • PediaPred Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • Prednisolone tablets Prescribing Information (FDA)

  • Prednisolone Monograph (AHFS DI)

  • Prednisolone MedFacts Consumer Leaflet (Wolters Kluwer)

  • Prednisolone Professional Patient Advice (Wolters Kluwer)

  • Prednisolone Acetate eent Monograph (AHFS DI)

  • Prelone Syrup MedFacts Consumer Leaflet (Wolters Kluwer)

  • Veripred 20 Prescribing Information (FDA)



Compare Pred-Ject-50 with other medications


  • Asthma, acute
  • Bronchopulmonary Dysplasia
  • Bullous Pemphigoid
  • Dermatitis
  • Immunosuppression
  • Inflammatory Conditions
  • Multiple Sclerosis
  • Nephrotic Syndrome
  • Pemphigoid
  • Pemphigus


Where can I get more information?


  • Your pharmacist can provide more information about prednisolone.

See also: Pred-Ject-50 side effects (in more detail)


Wednesday, 15 August 2012

Oruvail 200mg Capsules





1. Name Of The Medicinal Product



Oruvail 200


2. Qualitative And Quantitative Composition



Ketoprofen 200mg



3. Pharmaceutical Form



Controlled release capsules



4. Clinical Particulars



4.1 Therapeutic Indications



Oruvail is recommended in the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute articular and peri-articular disorders, (bursitis, capsulitis, synovitis, tendinitis), cervical spondylitis, low back pain (strain, lumbago, sciatica, fibrositis), painful musculo-skeletal conditions, acute gout, dysmenorrhoea and control of pain and inflammation following orthopaedic surgery.



Oruvail reduces joint pain and inflammation and facilitates increase in mobility and functional independence. As with other non-steroidal anti-inflammatory agents, it does not cure the underlying disease.



4.2 Posology And Method Of Administration



Adults: 100 - 200mg once daily, depending on patient weight and on severity of symptoms.



The maximum daily dose is 200mg. The balance of risks and benefits should be carefully considered before commencing treatment with 200mg daily, and higher doses are not recommended (see also section 4.4).



Elderly: The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.



Paediatric dosage not established.



Oruvail capsules are for oral administration. To be taken preferably with or after food.



Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).



4.3 Contraindications



Ketoprofen is contraindicated in patients who have a history of hypersensitivity reactions such as bronchospasm, asthmatic attacks, rhinitis, angioedema, urticaria or other allergic-type reactions to ketoprofen, any other ingredients in this medicine, ASA or other NSAIDs. Severe, rarely fatal, anaphylactic reactions have been reported in such patients (see section 4.8 Undesirable effects).



Ketoprofen is contraindicated in patients with hypersensitivity to any of the excipients of the drug.



Ketoprofen is also contraindicated in the third trimester of pregnancy.



Ketoprofen is contraindicated in the following cases:



- severe heart failure



- active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding)



- history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy



- haemorrhagic diathesis



- severe hepatic insufficiency



- severe renal insufficiency



- third trimester of pregnancy



4.4 Special Warnings And Precautions For Use



Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2 Posology and method of administration, and GI and cardiovascular risks below).



The use of ketoprofen with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided (see section 4.5 Interactions).



Elderly:



The elderly have an increased risk of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation which may be fatal (see Section 4.2 Posology and method of administration).



Cardiovascular, Renal and Hepatic impairment:



At the start of treatment, renal function must be carefully monitored in patients with heart impairment, heart failure, liver dysfunction, cirrhosis and nephrosis, in patients receiving diuretic therapy, in patients with chronic renal impairment, particularly if the patient is elderly. In these patients, administration of ketoprofen may induce a reduction in renal blood flow caused by prostaglandin inhibition and lead to renal decomposition. (see Section 4.3 Contra-indications)



NSAIDs have also been reported to cause nephrotoxicity in various forms and this can lead to interstitial nephritis, nephrotic syndrome and renal failure.



In patients with abnormal liver function tests or with a history of liver disease, transaminase levels should be evaluated periodically, particularly during long-term therapy. Rare cases of jaundice and hepatitis have been described with ketoprofen.



Cardiovascular and cerebrovascular effects



Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.



Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for ketoprofen.



Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ketoprofen after careful consideration. Similar consideration should be made before initiating long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).



Respiratory disorders:



Patients with asthma combined with chronic rhinitis, chronic sinusitis, and/or nasal polyposis have a higher risk of allergy to aspirin and/or NSAIDs than the rest of the population. Administration of this medicinal product can cause asthma attacks or bronchospasm, particularly in subjects allergic to aspirin or NSAIDs (see section 4.3).



Gastrointestinal bleeding, ulceration and perforation:



GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.



Some epidemiological evidence suggests that ketoprofen may be associated with a high risk of serious gastrointestinal toxicity, relative to some other NSAIDs, especially at high doses (see also section 4.2 and 4.3).



The risk of GI bleeding, ulceration or perforation is higher with increasing NSAlD doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and section 4.5).



NSAIDs should only be given with care to patients with a history of gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see Section 4.8 Undesirable effects).



Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding), particularly in the initial stages of treatment.



Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as corticosteroids, or anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as aspirin (see Section 4.5).



When GI bleeding or ulceration occurs in patients receiving ketoprofen, the treatment should be withdrawn.



SLE and mixed connective tissue disease:



In patients with systemic lupus erythematosis (SLE) and mixed connective tissue disorders, there may be an increased risk of aseptic meningitis (see Section 4.8 Undesirable effects).



Female fertility:



The use of ketoprofen, as with other NSAIDs, may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of ketoprofen should be considered.



Skin reactions:



Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Treatment should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.



Infectious disease:



As with other NSAIDs, in the presence of an infectious disease, it should be noted that the anti-inflammatory, analgesic and the antipyretic properties of ketoprofen may mask the usual signs of infection progression such as fever.



Visual disturbances:



If visual disturbances such as blurred vision occur, treatment should be discontinued.



Patients with active or a past history of peptic ulcer.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Anticoagulants (heparin and warfarin) and platelet aggregation inhibitors (i.e. ticlopidine, clopidogrel):



Increased risk of bleeding (see section 4.4)



If coadministration is unavoidable, patient should be closely monitored.



Lithium:



Risk of elevation of lithium plasma levels, sometimes reaching toxic levels due to decreased lithium renal excretion. Where necessary, plasma lithium levels should be closely monitored and the lithium dosage levels adjusted during and after NSAIDs therapy.



Other analgesics/NSAIDs (including cyclooxygenase-2 selective inhibitors) and high dose salicylates:



Avoid concomitant use of two or more NSAIDs (including aspirin) as this may increase the risk of adverse effects, particularly gastrointestinal ulceration and bleeding. (see Section 4.4 Special warnings and precautions for use).



Methotrexate:



Serious interactions have been recorded after the use of high dose methotrexate with NSAIDs, including ketoprofen, due to decreased elimination of methotrexate. At doses greater than 15mg/week:



Increased risk of haematologic toxicity of methotrexate, particularly if administered at high doses (> 15 mg/week), possibly related to displacement of protein-bound methotrexate and to its decreased renal clearance. At doses lower than 15mg/week: During the first weeks of combination treatment, full blood count should be monitored weekly. If there is any alteration of the renal function or if the patient is elderly, monitoring should be done more frequently.



Mifepristone:



NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.



Pentoxifylline:



There is an increased risk of bleeding. More frequent clinical monitoring and monitoring of bleeding time is required.



Antihypertensive agents (beta-blockers, angiotensin converting enzyme inhibitors, diuretics):



Risk of decreased antihypertensive potency (inhibition of vasodilator prostaglandins by NSAIDs).



Diuretics:



Risk of reduced diuretic effect. Patients and particularly dehydrated patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition. Such patients should be rehydrated before initiating coadministration therapy and renal function monitored when the treatment is started (see section 4.4 Special warnings and precautions for use).



Cardiac glycosides:



NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels.



Ciclosporin:



Increased risk of nephrotoxicity, particularly in elderly subjects.



Corticosteroids:



Increased risk of gastrointestinal ulceration or bleeding. (see Section 4.4 Special warnings and precautions for use).



Quinolone antibiotics:



Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.



Tacrolimus:



Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus, particularly in elderly subjects.



Thrombolytics:



Increased risk of bleeding.



Probenecid:



Concomitant administration of probenecid may markedly reduce the plasma clearance of ketoprofen.



Anti-platelet agents and Selective serotonin reuptake inhibitors (SSRIs):



Increased risk of gastrointestinal bleeding (section 4.4 Special warnings and precautions for use).



ACE inhibitors and Angiotensin II Antagonists:



In patients with compromised renal function (e.g. dehydrated patients or elderly patients the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure.



Zidovudine:



Increased risk of haematological toxicity when NSAIDs are given with zidovudine. There is evidence of an increased risk of haemarthroses and haematoma in HIV(+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen.



4.6 Pregnancy And Lactation



Pregnancy



Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, ketoprofen should not be given unless clearly necessary. If ketoprofen is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.



During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:



- cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);



- renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of the pregnancy, to:



- possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.



- Inhibition of uterine contractions resulting in delayed or prolonged labour.



Consequently, ketoprofen is contraindicated during the third trimester of pregnancy.



Lactation



No data are available on excretion of ketoprofen in human milk. Ketoprofen is not recommended in nursing mothers.



4.7 Effects On Ability To Drive And Use Machines



Patients should be warned about the potential for somnolence, dizziness or convulsions, drowsiness, fatigue and visual disturbances and be advised not to drive or operate machinery if these symptoms occur.



4.8 Undesirable Effects



The following CIOMS frequency rating is used, when applicable:



Very common (



The following adverse reactions have been reported with Ketoprofen in adults:



Blood and lymphatic system disorders



- rare: haemorrhagic anaemia, anaemia due to bleeding



- not known: agranulocytosis, thrombocytopenia, bone marrow failure, neutropenia



Immune system disorders



- rare: anaphylactic reactions (including shock)



Psychiatric disorders



- not known: mood altered



Nervous system disorders



- uncommon: headache, dizziness, somnolence



- rare: paraesthesia



- not known: convulsions, dysgeusia, depression, confusion, hallucinations, vertigo, malaise, drowsiness, reports of aseptic meningitis (especially in patients with existing auto-immune disorders such as systemic lupus erythematosis, mixed connective tissue disease) with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4 Special warnings and precautions for use).



Eye disorders



- rare: visual disturbances such as blurred vision (see section 4.4 Special warnings and precautions for use)



- not known: optic neuritis



Ear and labyrinth disorders



- rare: tinnitus



Cardiac disorders



- not known: heart failure, oedema



Vascular disorders



- not known: hypertension, vasodilatation



Respiratory, thoracic and mediastinal disorders



- rare: asthma, asthmatic attack



- not known: bronchospasm (particularly in patients with known hypersensitivity to ASA and other NSAIDs), rhinitis, non-specific allergic reactions, dyspnoea



Gastrointestinal disorders



- common: dyspepsia, nausea, abdominal pain, vomiting



- uncommon: constipation, diarrhoea, flatulence, gastritis



- rare: stomatitis, peptic ulcer



- very rare: pancreatitis (very rare reports of pancreatitis have been noted with NSAIDs)



- not known: exacerbation of colitis and Crohn's disease, gastrointestinal haemorrhage and perforation, gastralgia, melaena, haematemesis



Gastrointestinal bleeding may sometimes be fatal, particularly in the elderly (see section 4.4 Special warnings and precautions for use).



Hepatobiliary disorders



- rare: hepatitis, transaminases increased, elevated serum bilirubin due to hepatitis disorders



- not known: abnormal liver function, jaundice



Skin and subcutaneous disorders



- uncommon: rash, pruritis



- not known: photosensitivity reactions, alopecia, urticaria, angioedema, bullous eruption including Stevens-Johnson syndrome and toxic epidermal necrolysis, exfoliative and bullous dermatoses (including epidermal necrolysis, erythema multiforme), purpura



Renal and urinary disorders



- not known: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal



General disorders and administration site conditions



- uncommon: oedema, fatigue



- not known: headache, taste perversion



Investigations



- rare: weight increased



Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4 Special warnings and precautions for use).



In all cases of major adverse effects Oruvail should be withdrawn at once.



4.9 Overdose



Symptoms



Cases of overdose have been reported with doses up to 2.5g of ketoprofen. In most instances, the symptoms have been benign and limited to lethargy, drowsiness, nausea, vomiting and epigastric pain. Headache, rarely diarrhoea, disorientation, excitation, coma, dizziness, tinnitus, fainting, occasionally convulsions may also occur. Adverse effects seen after overdose with propionic acid derivatives such as hypotension, bronchospasm and gastro-intestinal haemorrhage should be anticipated.



In cases of significant poisoning, acute renal failure and liver damage are possible.



If renal failure is present, haemodialysis may be useful to remove circulating medicinal product.



Therapeutic measures:



There are no specific antidotes to ketoprofen overdosages. In cases of suspected massive overdosages, a gastric lavage is recommended and symptomatic and supportive treatment should be instituted to compensate for dehydration, to monitor urinary excretion and to correct acidosis, if present.



Owing to the slow release characteristics of Oruvail, it should be expected that ketoprofen will continue to be absorbed for up to 16 hours after ingestion.



Within one hour of ingestion, consideration should be given to administering activated charcoal in an attempt to reduce absorption of slowly-released ketoprofen.



Alternatively, in adults, gastric lavage, aimed at recovering pellets that may still be in the stomach, should be considered if the patient presents within 1 hour of ingesting a potentially toxic amount.



It should be possible to identify the pellets in the gastric contents. Correction of severe electrolyte abnormalities may need to be considered.



Good urine output should be ensured.



Renal and liver function should be closely monitored.



Patients should be observed for at least four hours after ingestion of potentially toxic amounts.



Frequent or prolonged convulsions should be treated with intravenous diazepam.



The benefit of gastric decontamination is uncertain.



Other measures may be indicated by the patient's clinical condition.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Ketoprofen overall has the properties of a potent non-steroidal anti- inflammatory agent. It has the following pharmacological effects:



Anti-inflammatory



It inhibits the development of carageenan-induced abscesses in rats at 1mg/kg, UV-radiation induced erythema in guinea pigs at 6mg/kg. It is also a potent inhibitor of PGE2 and PFG2∝ synthesis in guinea pig and human chopped lung preparations.



Analgesic



Ketoprofen effectively reduced visceral pain in mice caused by phenyl benzoquinone or by bradykinin following p.o. Administration at about 6mg/kg.



Antipyretic



Ketoprofen (2 and 6mg/kg) inhibited hyperthermia caused by s.c injection of brewer's yeast in rats and, at 1mg/kg hyperthermia caused by i.v. administration of anticoagulant vaccine to rabbits.



Ketoprofen at 10mg/kg i.v. did not affect the cardiovascular, respiratory, central nervous system or autonomic nervous systems.



5.2 Pharmacokinetic Properties



Ketoprofen is slowly but completely absorbed from Oruvail capsules. Maximum plasma concentration occurs after 6 - 8 hours. It declines thereafter with a half-life of about 8 hours. There is no accumulation on continued daily dosing. Ketoprofen is very highly bound to plasma protein



5.3 Preclinical Safety Data



No additional data of relevance to the prescriber.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Pellets



Sugar spheres



Colloidal anhydrous silica



Shellac



Ethylcellulose



Talc



Capsule shell-body



Gelatin



Erythrosine (E127)



Capsule shell – cap



Gelatin



Titanium dioxide (E171)



6.2 Incompatibilities



None stated



6.3 Shelf Life



36 months



6.4 Special Precautions For Storage



Store below 25°C in a dry place and protect from light.



6.5 Nature And Contents Of Container



UPVC/Aluminium foil blister or UPVC coated with PVDC aluminium foil blister containing either 28 capsules



6.6 Special Precautions For Disposal And Other Handling



None stated



7. Marketing Authorisation Holder



Sanofi-aventis



One Onslow Street



Guildford



Surrey



GU1 4YS



UK



8. Marketing Authorisation Number(S)



PL 04425/0599



9. Date Of First Authorisation/Renewal Of The Authorisation



21 September 2006



10. Date Of Revision Of The Text



11 May 2011



LEGAL CLASSIFICATION


POM